Cabozantinib shows promising activity in patients with MPPGs.
Related Posts
- Telaglenastat Plus Cabozantinib vs. Placebo Plus Cabozantinib in Advanced RCC Patients:CANTATA Phase 2 Trial
KEY TAKEAWAYS The Phase II CANTATA study, bearing the trial code NCT03428217, is a randomized,…
- Insurance Denial of Care for Randomized Controlled Trial-Eligible Patients: Incidence and Success Rate of Peer-To-Peer Authorization in Allowing Patients to Remain Trial-Eligible
Introduction: Insurance denials for clinical trials serve as a pertinent barrier for patients to remain…
- STRONG Trial: Predicting Durvalumab Response and Survival in mUTC Patients
KEY TAKEAWAYS The STRONG phase 3b trial tested immune checkpoint inhibitor therapy in previously treated…